Cytosorbents (CTSO) Profit After Tax (2010 - 2026)

Cytosorbents has reported Profit After Tax for 17 years, with the latest figure at -$5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 246.79% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at -$11.8 million (up 26.44% YoY), and the FY2025 full-year result was -$8.2 million, up 60.43% from the prior year.
• Profit After Tax for Q1 2026 stood at -$5.1 million, up from -$5.5 million in the prior quarter.
• The five-year high for Profit After Tax was $15.3 million in Q4 2023, with the low at -$12.2 million in Q3 2022.
• Historically, Profit After Tax has averaged -$4.4 million across 5 years, with a median of -$5.5 million in 2025.
• Annual changes were most pronounced in 2023 — Profit After Tax surged 2102.15% — and 2026, when it plunged 246.79%.
• Cytosorbents' Profit After Tax stood at -$766126.0 in 2022, then surged by 2102.15% to $15.3 million in 2023, then sank by 149.33% to -$7.6 million in 2024, then advanced by 27.36% to -$5.5 million in 2025, then advanced by 6.69% to -$5.1 million in 2026.
• The last three Profit After Tax figures came in at -$5.1 million (Q1 2026), -$5.5 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.